Download PDF
Thromb Haemost 2012; 108(04): 605-615
DOI: 10.1160/TH12-03-0153
Theme Issue Article
Schattauer GmbH

Alteration of the platelet transcriptome in chronic kidney disease

Hélène Plé
1   CHUQ Research Center/CHUL, Quebec, Quebec, Canada
2   Faculty of Medicine, Université Laval, Quebec, Quebec, Canada
,
Manon Maltais
3   Centre de Recherche de l'Hôpital du Sacré-Coeur de Montréal, and Faculty of Medicine, Université de Montréal, Montreal, Quebec, Canada
,
Aurélie Corduan
1   CHUQ Research Center/CHUL, Quebec, Quebec, Canada
2   Faculty of Medicine, Université Laval, Quebec, Quebec, Canada
,
Guy Rousseau
3   Centre de Recherche de l'Hôpital du Sacré-Coeur de Montréal, and Faculty of Medicine, Université de Montréal, Montreal, Quebec, Canada
,
François Madore
3   Centre de Recherche de l'Hôpital du Sacré-Coeur de Montréal, and Faculty of Medicine, Université de Montréal, Montreal, Quebec, Canada
,
Patrick Provost
1   CHUQ Research Center/CHUL, Quebec, Quebec, Canada
2   Faculty of Medicine, Université Laval, Quebec, Quebec, Canada
› Author Affiliations Financial support: This work was supported by Catalyst Grant: Pilot Projects in Aging No. IAP-99000 from the Canadian Institutes of Health Research (to P. P. and F.M.).
Further Information

Publication History

Received: 09 March 2012

Accepted after minor revision: 12 June 2012

Publication Date:
29 November 2017 (online)

Also available at
    Permissions and Reprints

Summary

Bleeding and thrombotic disorders are major complications affecting patients with chronic kidney disease (CKD). Exposure of circulating platelets to uraemic toxins and contact with artificial surfaces during dialysis induce platelet abnormalities and alter the platelet proteome. We hypothesised that these changes may be subsequent to changes in the composition and/or regulation of the platelet transcriptome. In this study, we investigated the circulating platelets of 10 CKD patients (i.e. five chronic haemodialysis patients and five stage 4 CKD uraemic patients) and five age- and sex-matched healthy subjects. We observed an alteration of the platelet messenger RNA (mRNA) and microRNA transcriptome in CKD patients. Impaired in uraemic platelets, the levels of some mRNAs and of most microRNAs appeared to be corrected by dialysis, which is consistent with a beneficial effect of dialysis and a mRNA regulatory role of platelet microRNAs. Reduced in platelets of uraemic patients, phosphatidylcholine transfer protein (PCTP) and WD repeat-containing protein 1 (WDR1) were found to be regulated by microRNAs, the latter of which involving hsa-miR-19b, a microRNA increased in platelets of uraemic patients and involved in platelet reactivity. These results suggest that an alteration of microRNA-based mRNA regulatory mechanisms may underlie the platelet response to uremia and entail the development of platelet-related complications in CKD.

Keywords

Chronic kidney disease - platelets - gene expression - mRNA - microRNA

 

  • References

  • 1 Collins AJ, Li S, Ma JZ. et al. Cardiovascular disease in end-stage renal disease patients. Am J Kidney Dis 2001; 38 (04) (Suppl. 01) S26-29.
    PubMedGoogle Scholar
  • 2 Foley RN, Murray AM, Li S. et al. Chronic Kidney Disease and the Risk for Cardiovascular Disease, Renal Replacement, and Death in the United States Medicare Population, 1998 to 1999. J Am Soc Nephrol 2005; 16: 489-495.
    CrossrefPubMedGoogle Scholar
  • 3 Sidhu MS, Dellsperger KC. Cardiovascular problems in dialysis patients: impact on survival. Adv Perit Dial 2010; 26: 47-52.
    PubMedGoogle Scholar
  • 4 Cheung AK, Sarnak MJ, Yan G. et al. Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients. Kidney Int 2000; 58: 353-362.
    CrossrefPubMedGoogle Scholar
  • 5 Xue JL, Frazier ET, Herzog CA. et al. Association of heart disease with diabetes and hypertension in patients with ESRD. Am J Kidney Dis 2005; 45: 316-323.
    CrossrefPubMedGoogle Scholar
  • 6 Libetta C, Sepe V, Esposito P. et al. Oxidative stress and inflammation: Implications in uremia and hemodialysis. Clin Biochem 2011; 44: 1189-1198.
    CrossrefPubMedGoogle Scholar
  • 7 Vaziri ND, Norris K. Lipid disorders and their relevance to outcomes in chronic kidney disease. Blood Purif 2011; 31: 189-196.
    CrossrefPubMedGoogle Scholar
  • 8 Boccardo P, Remuzzi G, Galbusera M. Platelet dysfunction in renal failure. Semin Thromb Hemost 2004; 30: 579-589.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 9 Rios DR, Carvalho MG, Lwaleed BA. et al. Hemostatic changes in patients with end stage renal disease undergoing hemodialysis. Clin Chim Acta 2010; 411: 135-139.
    CrossrefPubMedGoogle Scholar
  • 10 Kaw D, Malhotra D. Platelet dysfunction and end-stage renal disease. Semin Dial 2006; 19: 317-322.
    CrossrefPubMedGoogle Scholar
  • 11 Aggarwal A, Kabbani SS, Rimmer JM. et al. Biphasic effects of hemodialysis on platelet reactivity in patients with end-stage renal disease: a potential contributor to cardiovascular risk. Am J Kidney Dis 2002; 40: 315-322.
    CrossrefPubMedGoogle Scholar
  • 12 Kabbani SS, Watkins MW, Ashikaga T. et al. Platelet reactivity characterized prospectively: a determinant of outcome 90 days after percutaneous coronary intervention. Circulation 2001; 104: 181-186.
    CrossrefPubMedGoogle Scholar
  • 13 Thaulow E, Erikssen J, Sandvik L. et al. Blood platelet count and function are related to total and cardiovascular death in apparently healthy men. Circulation 1991; 84: 613-617.
    CrossrefPubMedGoogle Scholar
  • 14 Trip MD, Cats VM, van Capelle FJ. et al. Platelet hyperreactivity and prognosis in survivors of myocardial infarction. N Engl J Med 1990; 322: 1549-1554.
    CrossrefPubMedGoogle Scholar
  • 15 Rowley JW, Oler AJ, Tolley ND. et al. Genome-wide RNA-seq analysis of human and mouse platelet transcriptomes. Blood 2011; 118: e101-111.
    CrossrefPubMedGoogle Scholar
  • 16 Roth GJ, Hickey MJ, Chung DW. et al. Circulating human blood platelets retain appreciable amounts of poly (A)+ RNA. Biochem Biophys Res Commun 1989; 160: 705-710.
    CrossrefPubMedGoogle Scholar
  • 17 Schubert P, Devine DV. De novo protein synthesis in mature platelets: a consideration for transfusion medicine. Vox Sang 2010; 99: 112-122.
    CrossrefPubMedGoogle Scholar
  • 18 Cecchetti L, Tolley ND, Michetti N. et al. Megakaryocytes differentially sort mRNAs for matrix metalloproteinases and their inhibitors into platelets: a mechanism for regulating synthetic events. Blood 2011; 118: 1903-1911.
    CrossrefPubMedGoogle Scholar
  • 19 Weyrich AS, Denis MM, Schwertz H. et al. mTOR-dependent synthesis of Bcl-3 controls the retraction of fibrin clots by activated human platelets. Blood 2007; 109: 1975-1983.
    CrossrefPubMedGoogle Scholar
  • 20 Evangelista V, Manarini S, Di Santo A. et al. De novo synthesis of cyclooxygenase-1 counteracts the suppression of platelet thromboxane biosynthesis by aspirin. Circ Res 2006; 98: 593-595.
    CrossrefPubMedGoogle Scholar
  • 21 Walkowiak B, Kaminska M, Okroj W. et al. The blood platelet proteome is changed in UREMIC patients. Platelets 2007; 18: 386-388.
    CrossrefPubMedGoogle Scholar
  • 22 Marques M, Sacristan D, Mateos-Caceres PJ. et al. Different protein expression in normal and dysfunctional platelets from uremic patients. J Nephrol 2010; 23: 90-101.
    PubMedGoogle Scholar
  • 23 Tassies D, Reverter JC, Cases A. et al. Reticulated platelets in uremic patients: effect of hemodialysis and continuous ambulatory peritoneal dialysis. Am J Hematol 1995; 50: 161-166.
    CrossrefPubMedGoogle Scholar
  • 24 Schoorl M, Bartels PCM. Changes in platelet volume, morphology and RNA content in subjects treated with haemodialysis. Scand J Clin Lab Invest 2008; 68: 335-342.
    CrossrefPubMedGoogle Scholar
  • 25 Landry P, Plante I, Ouellet DL. et al. Existence of a microRNA pathway in anucleate platelets. Nat Struct Mol Biol 2009; 16: 961-966.
    CrossrefPubMedGoogle Scholar
  • 26 Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001; 25: 402-408.
    CrossrefPubMedGoogle Scholar
  • 27 Nagalla S, Shaw C, Kong X. et al. Platelet microRNA-mRNA coexpression profiles correlate with platelet reactivity. Blood 2011; 117: 5189-5197.
    CrossrefPubMedGoogle Scholar
  • 28 Griffiths-Jones S. The microRNA Registry. Nucleic Acids Res 2004; 32 (Database issue) D109-111.
    CrossrefPubMedGoogle Scholar
  • 29 Xiao F, Zuo Z, Cai G. et al. miRecords: an integrated resource for microRNA-target interactions. Nucleic Acids Res 2009; 37 (Database issue) D105-110.
    CrossrefPubMedGoogle Scholar
  • 30 Plante I, Davidovic L, Ouellet DL. et al. Dicer-derived microRNAs are utilized by the fragile X mental retardation protein for assembly on target RNAs. J Biomed Biotechnol 2006; 2006: 643-647.
    PubMedGoogle Scholar
  • 31 Levey AS, Bosch J P, Lewis JB. et al. A more accurate method to estimate glomeru-lar filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461-470.
    CrossrefPubMedGoogle Scholar
  • 32 Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009
    PubMedGoogle Scholar
  • 33 Vanholder R, Cornelis R, Dhondt A. et al. The role of trace elements in uraemic toxicity. Nephrol Dial Transplant 2002; 17 (Suppl. 02) 2-8.
    PubMedGoogle Scholar
  • 34 Tubek S, Grzanka P, Tubek I. Role of Zinc in Hemostasis: A Review. Biological Trace Element Res 2008; 121: 1-8.
    PubMedGoogle Scholar
  • 35 Foster M, Samman S. Zinc and redox signaling: perturbations associated with cardiovascular disease and diabetes mellitus. Antioxid Redox Signal 2010; 13: 1549-1573.
    CrossrefPubMedGoogle Scholar
  • 36 Kadota Y, Suzuki S, Ideta S. et al. Enhanced metallothionein gene expression induced by mitochondrial oxidative stress is reduced in phospholipid hydroperoxide glutathione peroxidase-overexpressed cells. Eur J Pharmacol 2010; 626: 166-170.
    CrossrefPubMedGoogle Scholar
  • 37 Fujii H, Nakai K, Fukagawa M. Role of Oxidative Stress and Indoxyl Sulfate in Progression of Cardiovascular Disease in Chronic Kidney Disease. Therap Apheresis Dialysis 2011; 15: 125-128.
    PubMedGoogle Scholar
  • 38 Pamuklar Z, Lee JS, Cheng H-Y. et al. Individual Heterogeneity in Platelet Response to Lysophosphatidic Acid. Arterioscl Thromb Vasc Biol 2008; 28: 555-561.
    CrossrefPubMedGoogle Scholar
  • 39 Cui MZ. Lysophosphatidic acid effects on atherosclerosis and thrombosis. Clin Lipidol 2011; 06: 413-426.
    CrossrefPubMedGoogle Scholar
  • 40 Di Minno G, Martinez J, McKean M-L. et al. Platelet dysfunction in uremia. Multifaceted defect partially corrected by dialysis. Am J Med 1985; 79: 552-559.
    CrossrefPubMedGoogle Scholar
  • 41 Vecino AM, Teruel JL, Navarro JL. et al. Phospholipase A2 activity in platelets of patients with uremia. Platelets 2002; 13: 415-418.
    CrossrefPubMedGoogle Scholar
  • 42 Bonomini M, Dottori S, Amoroso L. et al. Increased platelet phosphatidylserine exposure and caspase activation in chronic uremia. J Thromb Haemost 2004; 02: 1275-1281.
    CrossrefPubMedGoogle Scholar
  • 43 Vecino A, Navarro-Antolin J, Teruel J. et al. Lipid composition of platelets in patients with uremia. Nephron 1998; 78: 271-273.
    CrossrefPubMedGoogle Scholar
  • 44 Saj A, Lai EC. Control of microRNA biogenesis and transcription by cell signaling pathways. Curr Opin Genet Develop 2011; 21: 504-510.
    CrossrefPubMedGoogle Scholar
  • 45 Huntzinger E, Izaurralde E. Gene silencing by microRNAs: contributions of translational repression and mRNA decay. Nat Rev Genet 2011; 12: 99-110.
    CrossrefPubMedGoogle Scholar
  • 46 Guo H, Ingolia NT, Weissman JS. et al. Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature 2010; 466: 835-840.
    CrossrefPubMedGoogle Scholar
  • 47 Kondkar AA, Bray MS, Leal SM. et al. VAMP8/endobrevin is overexpressed in hyperreactive human platelets: suggested role for platelet microRNA. J Thromb Haemost 2010; 08: 369-378.
    CrossrefPubMedGoogle Scholar
  • 48 Sondermeijer BM, Bakker A, Halliani A. et al. Platelets in Patients with Premature Coronary Artery Disease Exhibit Upregulation of miRNA340* and miRNA624*. PLoS One 2011; 06: e25946.
    CrossrefPubMedGoogle Scholar